

## Accepted Manuscript

Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: is early treatment associated with improved outcomes?

Paresh Chaudhari, Carlos Vallarino, Ernest H. Law, Raafat Seifeldin


PII: S0168-8227(16)31503-0  
DOI: <http://dx.doi.org/10.1016/j.diabres.2016.10.020>  
Reference: DIAB 6784

To appear in: *Diabetes Research and Clinical Practice*

Received Date: 29 June 2016  
Revised Date: 27 September 2016  
Accepted Date: 23 October 2016

Please cite this article as: P. Chaudhari, C. Vallarino, E.H. Law, R. Seifeldin, Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: is early treatment associated with improved outcomes?, *Diabetes Research and Clinical Practice* (2016), doi: <http://dx.doi.org/10.1016/j.diabres.2016.10.020>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Evaluation of patients with type 2 diabetes mellitus receiving treatment during the pre-diabetes period: is early treatment associated with improved outcomes?

Paresh Chaudhari<sup>a</sup>, Carlos Vallarino<sup>b</sup>, Ernest H. Law<sup>c,d</sup>, Raafat Seifeldin<sup>c</sup>

<sup>a</sup> Formerly of Global Outcomes Research, Takeda Pharmaceuticals International, Inc., One Takeda Parkway, Deerfield, IL 60015, USA.

<sup>b</sup> Data Science Institute, Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL 60015, USA.

<sup>c</sup> Global Outcomes Research, Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL 60015, USA. <sup>d</sup> Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.

**Running head:**

Pretreatment in Type 2 Diabetes in the United States

**Corresponding author:**

*Raafat Seifeldin, PharmD, MS, PhD; Senior Director, Global Outcomes Research, Takeda Development Center Americas, Inc.; One Takeda Parkway, Deerfield, IL 60015*

*Tel: 224-554-6037; Email: rseifeldin@takeda.com*

**Funding sources:**

Supported by Takeda Pharmaceuticals International, Inc.

**Disclosures:**

Ernest Law was supported by the 2014-2016 UIC/Takeda Health Economics and Outcomes Research Fellowship

*Word count: 2,434 (excluding abstract, references, tables, figures)*

*Figures: 2, Tables: 3*

---

Download English Version:

<https://daneshyari.com/en/article/5587475>

Download Persian Version:

<https://daneshyari.com/article/5587475>

[Daneshyari.com](https://daneshyari.com)